RHJA
PRVB

Rice Hall James & Associates’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Rice Hall James & Associates’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-72,176
Closed -$1.74M – 274
2023
Q1 		$1.74M Sell
72,176
-109,804
-60% -$1.38M 0.1% 199
2022
Q4 		$1.92M Sell
181,980
-39,621
-18% -$320K 0.11% 193
2022
Q3 		$997K Sell
221,601
-4,184
-2% -$19.1K 0.06% 233
2022
Q2 		$903K Buy
225,785
+5,720
+3% +$27.1K 0.04% 232
2022
Q1 		$1.61M Buy
220,065
+13,850
+7% +$82.8K 0.06% 223
2021
Q4 		$1.16M Sell
206,215
-35,196
-15% -$223K 0.04% 238
2021
Q3 		$1.54M Buy
241,411
+5,487
+2% +$35.3K 0.06% 231
2021
Q2 		$1.99M Sell
235,924
-11,271
-5% -$90.9K 0.07% 221
2021
Q1 		$2.59M Buy
247,195
+79
+0% +$1.11K 0.08% 167
2020
Q4 		$4.19M Buy
247,116
+16,243
+7% +$243K 0.15% 117
2020
Q3 		$2.96M Buy
230,873
+84,917
+58% +$1.07M 0.12% 128
2020
Q2 		$2.06M Buy
145,956
+10,804
+8% +$136K 0.09% 147
2020
Q1 		$1.24M Buy
135,152
+76,584
+131% +$987K 0.07% 181
2019
Q4 		$873K Buy
+58,568
New +$522K 0.03% 234

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Rice Hall James & Associates's PRVB Position: Q2 2023 in Review

Rice Hall James & Associates sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 72,176 shares — an estimated $1.74M sold.

Rice Hall James & Associates first reported a position in PRVB in Q4 2019 and held it in 14 quarters. The position peaked at $4.19M in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Rice Hall James & Associates reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Rice Hall James & Associates sold 72,176 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.74M.
  • Rice Hall James & Associates first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
  • Rice Hall James & Associates's Provention Bio, Inc. Common Stock position peaked at $4.19M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Rice Hall James & Associates's 13F filing for Q2 2023, filed 24 Jul 2023.